Carboplatin dosing accounting for the renal and hematologic status of patients.
Using AUC-based dosing compensates for variations in renal function between and within individual patients. It does not adjust for other factors such as previous chemotherapy, previous radiotherapy, or performance status. One empiric method to adjust for these factors would be reduction of the ideal AUC. However, because AUC-based dosing accounts for variations in renal function, this would not be an appropriate method to adjust dosing based solely on renal function changes.
Busse
Tom
T
Department of Pharmacy, Gottlieb Memorial Hospital, Melrose Park, IL. tom_busse@ghr.org
D058186:Acute Kidney Injury / Q000517:prevention & control; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001774:Blood Chemical Analysis; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003404:Creatinine / Q000652:urine*; D004305:Dose-Response Relationship, Drug; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D008991:Monitoring, Physiologic; D009369:Neoplasms / Q000188:drug therapy / Q000451:nursing; D009503:Neutropenia / Q000517:prevention & control; D012307:Risk Factors
D003404:Creatinine; D016190:Carboplatin